European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading

MT Newswires Live
14 Feb

European equities traded in the US as American depositary receipts were tracking slightly lower late Thursday morning, declining 0.04% to 1,402.70 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by pharmaceutical company Ascendis Pharma (ASND) and biotech company BioNTech (BNTX), which climbed 14.9% and 6.3% respectively. They were followed by biopharmaceutical company Grifols (GRFS) and biotech company and Evaxion Biotech (EVAX), which rose 5.6% and 1.5% respectively.

The decliners from continental Europe were led by consumer goods company Unilever (UL) and pharmaceutical company Novo Nordisk (NVO), which fell 5% and 3% respectively. They were followed by telecommunications company Nokia (NOK) and financial services company Banco Santander (SAN), which were off 0.5% each.

From the UK and Ireland, the gainers were led by biopharmaceutical company Amarin (AMRN) and pharmaceutical company Silence Therapeutics (SLN), which increased 6.7% and 3.3% respectively. They were followed by alcoholic beverage company Diageo (DEO) and biopharmaceutical company NuCana (NCNA), which were up 2.6% and 2.3% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company TC Biopharm (TCBP) and tobacco company British American Tobacco (BTI), which shed 16.3% and 9.1% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and financial services company Barclays (BCS), which were down 6.7% and 4.8% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10